The Hive is an innovation initiative for biotech and pharmaceutical start-ups, committed to promoting collaboration and inspiration across the Pharma & Life Sciences industry by providing an opportunity for participating companies to advance their research, and for others to learn from their experiences. The goal of The Hive is to help foster the discoveries that happen in these early-stage, start-up environments, ensuring that the route to market for new innovations is accelerated.
The six participating companies – the second intake of start-ups to The Hive – were specially selected for their commitment to cutting-edge science in emerging areas of research. All six demonstrate significant potential to impact how future treatments are researched and developed. As members of The Hive, each company will receive support, complimentary training, and access to Elsevier’s suite of R&D solutions for 18 months to support their groundbreaking and innovative work in some of the hottest research areas.
Enter your email address to follow The Hive and get the latest updates on participants and milestones – followed by the email address submission box.
Questions, comments or inquiries about The Hive? Send us a message.
Meet the participants
Exemplifying the fresh, innovative and agile world of R&D that is taking place outside the walls of Big Pharma, our four participants have the potential to change the industry’s landscape and improve the lives of patients. Discover the six companies selected to take part in The Hive and meet the people who make them tick.
4P-Pharma, from France, bridges the gap between academic discoveries and the pharma industry, helping to mature early-stage technologies from the drug discovery level to clinical phase and commercialization. The company was created in response to the urgent need to increase the number of innovative therapeutics entering the developing drug pipeline for cancer and inflammatory diseases.
Beacon Discovery, from San Diego, CA, USA, comprised of a group of scientists who have worked together for more than a decade, leverages academic and pharma partnerships to advance research around translating G-Protein Coupled Receptors (GPCRs) into new therapeutics. The company’s mission is to efficiently identify and advance molecules targeting GPCRs from concept to clinic.
Exscientia, from Scotland, UK, uses systems driven by Artificial Intelligence to actively learn best practices from vast repositories of discovery data, and design millions of novel, project-specific compounds. The company – the first to automate drug design – is at the forefront of small molecule drug discovery.
LegoChem Biosciences, from South Korea (the first Hive participant from Asia); with its expertise in medicinal chemistry, develops next generation Antibody-Drug Conjugates (ADC) utilizing its proprietary ADC platform ConjuAll TM, providing solutions for site-specific conjugation, linker stability and efficient payload release—which are three major unmet needs in ADC development.
Sigilon Therapeutics, from Cambridge, MA, USA, develops treatments based on a platform enabling a new therapeutic modality -- immune-privileged living therapeutic implants -- for chronic diseases including hematologic, enzyme deficiency, endocrine and metabolic disorders. The aim of these implants is to provide long-term, more natural control for diseases that are currently treated with intermittent injection or infusion in order to restore health and improve quality of life.
Unum Therapeutics, from Cambridge, MA, USA, is a clinical-stage biopharmaceutical company focused on the development of novel immunotherapy products based on its universal Antibody-Coupled T-cell Receptor (ACTR). When combined with an antibody that recognizes a target on the surface of tumor cells, the ACTR receptor can direct an individual’s T-cells to kill the tumor. Unlike other approaches (such as CAR-T or TCR), Unum’s therapy is not restricted to a particular target and may be used in many different cancer types.
Elsevier R&D Solutions - Pharma & Life Sciences Solution Finder
From discovery to post-market, we offer solutions that can help you drive commercial success and manage risk. Answer a few questions to see which of our solutions can help you.
Already know which solutions are right for you?
Learn more about Elsevier's R&D solutions for drug discovery
and development utilized by The Hive participants
Improve R&D productivity with a chemistry research solution that delivers experimental facts on chemical structures, properties, reactions and procedures.
Learn more about Reaxys
Get started with Reaxys
Increase the discovery of biomedical evidence to support critical life sciences functions, with access to the world's most comprehensive biomedical literature database.
Learn more about Embase
Get started with Embase
Enable better understanding of biological processes underlying disease progression and treatment response, with a solution that helps researchers interpret experimental data from scientific literature.
Learn more about Pathway Studio
Get started with Pathway Studio